Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Invest New Drugs. 2014 Dec 9;33(2):371–379. doi: 10.1007/s10637-014-0194-2

Figure 1. The combination of belinostat and azacitidine induced a significant upregulation of MDR1 compared with AZA alone.

Figure 1

Quantitative RT-PCR analysis of MDR1 at baseline and day 5 following treatment in cycle 1 revealed a relative change in MDR1 expression at day 5 (compared with baseline), that was significantly higher in the combination arm (p=0.0023) compared with the azacitidine alone arm.